PIPERACILLIN
Sponsors
UZ Leuven, Hellenic Institute For The Study Of Sepsis, Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau, Assistance Publique Hopitaux De Paris, Centre Hospitalier Universitaire De Nimes
Conditions
Bacterial PneumoniaCritical Patients admitted to the ICUFebrile neutropeniaHealthy SubjectsHematopoietic Stem Cell TransplantationInfectious diseasesIntensive CareNeutropenia
Phase 1
Phase 3
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
CompletedNCT02493764
Start: 2015-11-24End: 2019-04-03Updated: 2020-04-16
A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial)
Active, not recruitingCTIS2022-502962-26-00
Start: 2023-09-14Target: 190Updated: 2025-11-03
COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit. Multicentric non-inferiority randomised controlled trial
CompletedCTIS2023-505108-52-00
Start: 2023-12-20End: 2025-09-19Target: 628Updated: 2025-04-23
BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis
Not yet recruitingCTIS2024-516849-39-01
Target: 600Updated: 2025-12-02
BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection
Not yet recruitingCTIS2025-522819-42-01
Target: 672Updated: 2026-08-06
Phase 4
Clinical impact of pharmacokinetic monitoring of antibiotics in critically ill patients
Not yet recruitingCTIS2023-504480-17-00
Target: 384Updated: 2024-03-11
SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non-inferiority trial
RecruitingCTIS2022-500389-84-00
Start: 2024-02-16Target: 410Updated: 2025-11-13
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study
to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
Not yet recruitingCTIS2024-516232-10-00
Target: 200Updated: 2025-10-17
Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)
Not yet recruitingCTIS2025-524264-38-00
Target: 136Updated: 2026-05-05